Endocrine clinical trials
2009-0210: Phase II study of Ultratrace iobenguane I131 in patients with malignant relapsed/refractory pheochromocytoma/paraganglioma to determine if the agent can help reduce the amount of or allow you to stop taking blood pressure drugs because of the cancer, and if the drug is useful as a treatment for the cancer and reduced pain.
2017-0202: A Phase I oral LOXO-292 advanced solid tumors, including RET-fusion non-small cell lung cancer and medullary thyroid cancer, and other tumors with increased RET activity.
2017-0418: Phase I/II study of TRK inhibitor LOXO-195 with NTRK fusion (previously treated) or non-fusion NTRK altered cancers.
Leukemia clinical trials
COGAHOD1331: A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults.
COGAALL1131: A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (IND#73789, NSC#732517) in Patients with PH-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations.
2016-0316: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4).
2016-0341: A Phase 1 Safety Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced with Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
COGAALL1331: Phase III clinical trial of blinatumomab in first relapse of childhood B-Lymphoblastic Leukemia (B-ALL).
Neuro-oncology clinical trials
2017-0085: Ex-vivo expanded allogeneic NK cells for the treatment of solid tumors of pediatric origin in Children and Young Adults.
COGAGCT1531: A Phase 3 Study of active surveillance for low risk and a randomized trial of carboplatin versus cisplatin for standard risk pediatric and adult patients with germ cell tumors.
2018-0178: ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Recurrent/Refractory Pediatric H3 K27M Gliomas (ONC014)
2013-0765: Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent/refractory malignant posterior fossa tumors of the central nervous system (CNS). This is the New Opportunity, Advancing Hope (NOAH) Protocol.
2014-0692: A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients with Advanced Solid Tumors and central nervous system (CNS) tumors.
2014-0135: A Phase I study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) with Temsirolimus in Children with Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (DIPG).
Phase I studies/investigational cancer therapeutics
2011-0953: A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors.
2017-0567: The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the performance (both safety and efficacy) of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced solid tumors, multiple myeloma or B cell non-Hodgkin lymphoma with a genomic variant known to be a target of an FDA-approved anti-cancer drug or to predict sensitivity to an FDA-approved anti-cancer drug.
Sarcoma and solid tumor clinical trials
2017-0672: Clinical study to assess efficacy and safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types).
2015-0720: Phase I study of Aerosol Gemcitabine in patients with Solid Tumors and Pulmonary Metastases.
2015-1126: Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumors, rhabdomyosarcoma and/or other solid tumors with known ErbB pathway deregulation regardless of tumor histology.
2015-0929: A Phase I/II, Multicenter, Open-Label Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients with Previously Treated Solid Tumors.
2014-0692: Phase I trial of dasatinib, cyclophosphamide and temsirolimus for advanced pediatric solid tumors and central nervous system (CNS) tumors.
2016-0023: Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma.
COGAEWS1221: Phase III trial evaluating the addition of the IGF-1R monoclonal antibody ganitumab to the multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma.
COGARST1321: Study of Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III trial of preoperative chemoradiation or preoperative radiation plus or minus pazopanib in pediatric and adult patients newly diagnoses with unresected intermediate- and high-risk NRSTS.
Stem cell and cell therapy trials for pediatric/adult patients
2017-0769: Multi-center, Open-Label, Phase 3 Trial of ATA129 for Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab (MATCH) study
2017-0771: Multicenter, Open Label, Phase 3 trial of ATA129 for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study).
2018-0196: Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in patients with Hemoglobinopathies.
2013-1018: A Phase I study of CD19+ CAR (chimeric antigen receptor) T cells for patients with advanced Lymphoid Malignancies.
2016-0051: A Phase II study of Cord Blood ex-vivo MPC Expansion plus Fucosylation to enhance homing and engraftment.
2015-0313: A Phase II study of personalized natural killer (NK) cell immunotherapy in Cord Blood Transplantation.
2014-0279: Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by ex vivo Expansion in Patients with BK Virus Infection and JC Virus Infection
2016-0137: Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation
2016-0403: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute Graft vs host Disease (aGvHD)
2015-0576: Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia
2016-0748: A Phase III, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease (VOD prophylaxis) in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
2017-0342: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogeneic stem cell transplantation (REACH 3).
2010-0654: Nutrition Intervention for patients with acute lymphoblastic leukemia (ALL) treated with prednisone and/or dexamethasone. Goal: to learn if intervention can help prevent rapid excess weight gain in pediatric patients.
COG-ALTE07C1: Study of the neuropsychological, social, emotional, and behavioral outcomes in children with cancer.
Registry trials for pediatric patients
2014-0938: This protocol seeks to gather biospecimens over a period of years for all tumor types. During the clinical research study, samples of normal and tumor tissue, as well as blood, bone, marrow, and bodily fluid will be collected over time. This is part of the Adaptive Patient-Oriented Longitudinal Learning and Optimization (APOLLO) Moon Shot™ Platform at MD Anderson.
A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft vs host disease after allogeneic stem cell transplantation (REACH 3)